This website uses cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.

Our privacy statement:

Rob Ludding

Rob Ludding

Of counsel

Corporate Law

Rob Ludding is associated with De Clercq as an of counsel. During the course of over 43 years as an attorney and corporate lawyer, Rob has assisted companies, government, semi-government and non-profit organisations in a variety of sectors. Since August 2017, he has been putting his comprehensive and valuable knowledge and experience to use in his work at De Clercq on matters relating to his areas of expertise, specifically Dutch and European competition law (including its relationship with intellectual property), European law and state aid law.

Education and career

After studying Dutch and European law at the University of Amsterdam, Rob started his career as an attorney in 1974 at the firm formerly known as Blackstone, Rueb & Van Boeschoten (now De Brauw Blackstone Westbroek). After an interlude as secretary to the board at an electrical engineering company, he continued his law career in 1980 as an in-house lawyer at Shell International in London and The Hague. In this position, he was responsible for the legal aspects of all European oil, gas and chemicals activities undertaken by the Royal Dutch Shell Group with respect to competition law and European laws and regulations. From 1992 to 2005, Rob was an attorney/partner at Pels Rijcken & Droogleever Fortuijn, the firm of the State Advocate, after which he served as an of counsel for six years at the English/American company DLA Piper in Amsterdam. His work there involved European and competition law advisory and litigation practice. Rob then went on to conduct his own practice within MBF Advocaten in Rijswijk. From 1998 to 2005, Rob was also an attorney for the Netherlands Competition Authority (Nederlandse Mededingingsautoriteit), now known as the Netherlands Authority for Consumers and Markets (Autoriteit Consument en Markt). In this role, he was involved in matters such as all principle court proceedings to which the NMa was a party.

Rob's daily practice

‘Broadly speaking, I am a specialist in the field of European law that has a direct impact on the Dutch legal order in numerous areas, and often unexpectedly so. For example, I am involved in competition disputes between companies (the Competition Act is a consequence of previous European legislation) regarding exclusivity agreements, non-competition schemes, abuse of dominant economic positions, and anti-competitive state aid. In that context, I litigate (also as a consultant to other law firms) against parties such as financial institutions, but I also support biodynamic farmers in their dispute with the State and the Netherlands Enterprise Agency (RVO) about the implementation of the European Phosphate Directive. I am also regularly involved in disputes about exercising intellectual property rights, for example with respect to what you can and cannot do with your exclusive right as an IP right holder. This is an issue that has fascinated me since my graduate studies, and about which I have published quite a lot of material.’

Stay up to date

The latest developments

Corporate Law

Governance in healthcare (III): the supervisory board

10 March 2025

Governance involves organizing an institution in such a way that the quality of management and oversight is ensured. In recent years, this has become an increasingly important topic in the healthcare sector. The underlying idea is that good governance will enhance the quality of care. There are several key points to consider in the healthcare sector, which will be addressed in the blog series on governance in healthcare. This blog discusses the supervisory board.

Read more

Corporate Law

Governance in healthcare (II): The Healthcare Governance Code

20 February 2025

Governance involves organizing an entity in such a way that the quality of management and its supervision is ensured. In recent years, this has become an increasingly important topic in the healthcare sector. The idea is that good governance will improve the quality of care. There are several points of attention for the healthcare sector to consider, which will be discussed in the blog series on Governance in Healthcare. This blog will discuss the Healthcare Governance Code.

Read more

Corporate Law

A deal is a deal: Good Leaver receives only the nominal value for their skhares

13 February 2025

Many shareholders' agreements include provisions for the event that a shareholder leaves. It is usually agreed that this shareholder is obliged to transfer their shares to the other shareholders or the company. The price that a shareholder receives from the other shareholders or the company often depends on the reason for their departure. A shareholder who has proven their value to the company and has adhered to the agreements ('good leaver') usually receives a higher price than someone who leaves due to, for example, fraud, theft, dismissal as a director or employee, or failure to comply with the agreements ('bad leaver'). A recent ruling by the Amsterdam District Court confirms the importance of properly documenting such agreements in the shareholders' agreement.

Read more